An important aspect of regenerative medicines is optimizing the supply and manufacturing of important components, such as viral vectors, which are crucial for the delivery of cell and gene therapies.
Improving yield of viral vectors will primarily be achieved via scale-up, process improvements, and cell line development, says Emily Moran, senior vice-president of Vector Manufacturing and Supply Chain, Center for Breakthrough Medicines. Scale-up will go from the standard 200-L volume to 2000-L volume. Process improvements include alternating tangential flow filtration (ATF) on the production bioreactor, novel DNA for transfection, improved primary and polishing chromatography columns, and improved drug product formulation, Moran emphasizes.
